Tag: Eli Lilly and Co

2024-09-25

Novo Nordisk CEO testifies at Senate over weight loss drug prices

No Comments
Business

Novo Nordisk‘s top executive faced a Senate grilling on Tuesday over the high prices of the company’s weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the U.S.  Novo Nordisk CEO Lars Fruergaard Jørgensen did not explicitly promise lawmakers at a Senate Health, Education, Labor and Pensions Committee hearing in Washington, D.C., that he would…

Read More

2024-09-12

Eli Lilly to boost output of weight loss, diabetes, Alzheimer’s drugs

No Comments
Business

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said it will invest $1.8 billion to boost manufacturing for its newly approved Alzheimer’s drug and highly popular weight loss and diabetes treatments, among other medicines, in Ireland.  The pharmaceutical…

Read More

2024-09-04

Weight loss drugs cut Covid-19 deaths, study finds

No Comments
Business

People taking the key component of blockbuster weight loss drugs Ozempic and Wegovy were less likely to die of Covid-19 or suffer adverse effects from the virus, researchers found in a new study. People who were already being treated with a 2.4 mg dose of the drug semaglutide — the active ingredient in pharma titan Novo Nordisk’s Ozempic and…

Read More

2024-08-28

Eli Lilly releases new, cheaper form of weight loss drug

No Comments
Business

Eli Lilly on Tuesday released a new form of its weight loss drug Zepbound for roughly half its usual monthly list price to reach millions of patients without insurance coverage for the popular injection, such as those with Medicare.  The move also aims to expand the supply of Zepbound in the U.S. as demand skyrockets, and to ensure eligible…

Read More

2024-08-09

Eli Lilly (LLY) earnings Q2 2024

No Comments
Business

Eli Lilly on Thursday reported second-quarter earnings and revenue that blew past expectations and hiked its full-year revenue outlook by $3 billion as sales of its blockbuster diabetes drug Mounjaro and weight loss injection Zepbound spike. Shares of Eli Lilly closed more than 9% higher on Thursday. The drugmaker now expects revenue for the year to come in between…

Read More